Focal Therapy for Localized Prostate Cancer

a study on Prostate Cancer

Summary

Eligibility
for males ages 18 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at La Jolla, California
Dates
study started
completion around
Principal Investigator
by Juan Javier-DesLoges

Description

Summary

This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.

Official Title

A Prospective Registry and Longitudinal Study of Patients Undergoing Focal Therapy for Localized Prostate Cancer

Details

This observational study will serve to collect data from medical record and review questionnaires before and after focal ablation of prostate tissue. All enrolled subjects will have already undergone or scheduled to receive the focal therapy as part of their prostate cancer treatment.

Keywords

Prostate Cancer, Focal Therapy, High Intensity Frequency Ultrasound, Transurethral Ultrasound Ablation, Cryoablation, Irreversible Electroporation, Prostatic Neoplasms

Eligibility

You can join if…

Open to males ages 18 years and up

  • Subject has elected or already undergone focal therapy as their standard of care treatment method and declined alternative treatment (active surveillance, radical prostatectomy, and radiation therapy)
  • PSA ≤ 20
  • Ability to complete informed consent form

You CAN'T join if...

  • Contraindication to follow-up multi parametric MRI or prostate biopsy
  • Unable to tolerate general or regional anesthesia

Location

  • University of California, San Diego accepting new patients
    La Jolla California 92121 United States

Lead Scientist at UCSD

  • Juan Javier-DesLoges
    Associate Physician, Urology, Vc-health Sciences-schools. Authored (or co-authored) 40 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT06270043
Study Type
Observational [Patient Registry]
Participants
Expecting 500 study participants
Last Updated
Contact us about this trial